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BACKGROUND: The SOURCE 3 Registry (SAPIEN Aortic Bioprosthesis 
European Outcome) is a European multicenter, observational registry of 
the latest generation of transcatheter heart valve, the SAPIEN 3 (Edwards 
Lifesciences, Irvine, CA). Its purpose is to document outcomes of clinical 
safety and performance after European approval was given.
METHODS: Here, we present the 30-day outcome of the SOURCE 3 
Registry. All data are self-reported, and all participating centers have 
committed to support their consecutive experience with the SAPIEN 3 
transcatheter heart valve, dependent on patient consent, before the start 
of the study. Adverse events are defined with Valve Academic Research 
Consortium 2 criteria and adjudicated by an independent clinical events 
committee.
RESULTS: A total of 1950 patients from 80 centers in 10 countries were 
enrolled between July 2014 and October 2015. Of those, 1947 patients 
underwent transcatheter aortic valve implantation (TAVI) with the SAPIEN 3 
(mean age, 81.6±6.6 years; 48.1% female). Main comorbidities included 
coronary artery disease (51.5%), renal insufficiency (27.4%), diabetes 
mellitus (29.5%), chronic obstructive pulmonary disease (16.0%), and a 
mean logistic EuroSCORE of 18.3±13.2. Transfemoral access was used 
in 87.1% (n=1695); nontransfemoral, in 252 patients. Conscious sedation 
was used in 59.9% of transfemoral procedures, and in 50% of patients, 
TAVI was performed without aortic balloon valvuloplasty. Implantation 
success (1 valve in the intended location) was 98.3%. Conversion to 
conventional surgery (0.6%) and use of cardiopulmonary bypass (0.7%) 
were rare. Adverse events were low, with site-reported 30-day all-cause 
mortality of 2.2%, cardiovascular mortality of 1.1%, stroke of 1.4%, major 
vascular complications of 4.1%, life-threatening bleeding of 5%, and post-
TAVI pacemaker implantation of 12%. Moderate or greater paravalvular 
regurgitation was observed in 3.1% of reporting patients.
CONCLUSIONS: Results from the SOURCE 3 Registry demonstrate 
contemporary European trends and good outcomes of TAVI in daily 
practice when this third-generation TAVI device is used.
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Transcatheter aortic valve implantation (TAVI) has be-come the gold-standard treatment for patients unsuit-able for surgical aortic valve replacement (sAVR).1 
Previous randomized trials have also proven their value in 
patients at high risk for sAVR, which has led to a rapid in-
crease of TAVI procedures performed worldwide.2,3 Results 
from the PARTNER 2 trial (Placement of Aortic Transcath-
eter Valves 2) on intermediate-risk patients randomized to 
TAVI or sAVR have again demonstrated noninferiority for 
TAVI, with even a higher survival in patients feasible for a 
transfemoral (TF) approach.4 These trials were performed 
with the SAPIEN and SAPIEN XT transcatheter heart valve 
(THV) (Edwards Lifesciences, Irvine, CA).
Although randomized trials are excellent in assessing 
the value of a new technology in a selected cohort suit-
able for direct comparison with the gold-standard treat-
ment, as in the case of TAVI versus sAVR, they do not 
provide information on the results achievable with a new 
technology in larger patient populations and daily prac-
tices. Thus, the SOURCE (SAPIEN Aortic Bioprosthesis 
European Outcome) family of registries were initiated in 
2007 with the SOURCE Registry, a postapproval registry 
on the use of the SAPIEN THV (Edwards Lifesciences) to 
observe safety and performance of this THV under real-
world conditions.5
In recent years, THV technology in general and the 
SAPIEN prosthesis in particular were further developed 
to address shortcomings of TAVI identified in early stud-
ies. The SAPIEN 3, the latest generation of this balloon-
expandable THV, contains modifications that could po-
tentially improve implantation, facilitate TF access, and 
reduce strokes, vascular complications, and paravalvu-
lar leakages. The 30-day results of the first 150 patients 
treated were used to gain approval from European au-
thorities and have been reported previously.6,7
Data on the experience of the SAPIEN 3 postmarket-
ing approval were collected in Europe and North America 
at the same time. The results of the North American reg-
istry, with a design similar to SOURCE 3, and the out-
comes of a propensity-matched comparison with sAVR 
were recently published.8,9
We now present the patient and procedural character-
istics and 30-day outcomes of the SOURCE 3 Registry, 
the European postapproval multicenter and observation-
al registry with the SAPIEN 3.
METHODS
Registry Design and Purpose of This Report
In this article, we present the 30-day outcome of patients who 
underwent TAVI with a SAPIEN 3 in Europe after postmarked 
approval and were enrolled in the SOURCE 3 Registry. This in 
particular includes data on THV implantation and outcomes such 
as stroke, vascular complications, and paravalvular leakage.
The study was supervised by the SOURCE 3 Registry 
administration (online-only Data Supplemental) and approved 
by the institutional review boards of the participating centers 
(online-only Data Supplement), and all participants gave written 
informed consent.
THV and Delivery Devices
The SAPIEN 3 contains bovine pericardial leaflets that are 
mounted inside a cobalt-chromium alloy frame. An external 
polyethylene terephthalate fabric seal was added to the stent 
frame.
The prosthesis is delivered via the TF route with the 
Commander delivery catheter (Edwards Lifesciences), which 
is compatible with 14F (23 and 26 mm) and 16F (29 mm) 
expandable introducer sheaths. The Certitude delivery catheter 
(Edwards Lifesciences) can be used for TAVI using the transapi-
cal, transaortic, transcarotid, and subclavian approaches and 
is implanted through 18F (23 and 26 mm) or 21F (29 mm) 
sheaths. Both delivery systems contain an integrated nose 
cone on the tip of the catheter.
Definitions and Data Collection
All data were entered in the electronic data capture system by the 
participating centers and monitored by Edwards Lifesciences. 
Clinical Perspective
What Is New?
• The 30-day results of the SOURCE 3 Registry 
(SAPIEN Aortic Bioprosthesis European Outcome) 
demonstrate that transcatheter aortic valve implan-
tation with the SAPIEN 3 results in high procedural 
success with low procedural complications and 
excellent postimplantation hemodynamics.
• Moderate to severe paravalvular leakage appears to 
be lower with the SAPIEN 3 than with prior versions 
of this transcatheter heart valve.
• Rates of pacemaker implantation are higher with the 
SAPIEN 3 than with earlier generations of this valve.
• This, in combination with the growing experience 
of patient selection, procedure planning, execution, 
and postoperative care, has led to one of the best 
short-term outcomes ever reported after transcath-
eter aortic valve implantation.
What Are the Clinical Implications?
• These results demonstrate favorable outcomes with 
this third-generation transcatheter heart valve in 
clinical practice; they could serve as a benchmark 
for future studies.
• Although these findings may encourage heart teams 
to consider broader indications for transcatheter 
aortic valve implantation, future trials are needed 
to identify the patient population that benefits most 
from this technique.
• How transcatheter aortic valve implantation will ben-
efit patient outcome in the long term remains to be 
seen.
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Patients are assessed at discharge, after discharge (30 days), 
at 1 year, and annually up to 5 years after implantation. All 
study end points were defined per the VARC-2 (Valve Academic 
Research Consortium 2) criteria. Implantation success was 
defined as 1 valve implanted at the intended site by 1 attempted 
procedure. Outcomes measured in the SOURCE 3 Registry were 
all-cause death, cardiac death, stroke, major vascular complica-
tions, life-threatening bleeding, acute kidney injury, permanent 
pacemaker insertion, procedural complications, functional sta-
tus, and echocardiographic assessment of valve function.
Review and adjudication of key clinical events in the elec-
tronic database were performed by an independent clini-
cal events committee. All echocardiographic data were site 
reported. All data used in the analysis were as of July 11, 
2016, and this has resulted in minor variations in the outcomes 
reported in this publication compared with the original presen-
tation of the data by Wendler et al at EuroPCR 2016.
Statistical Analysis
Continuous variables are presented as mean±SD or median 
(quartiles 1 and 3) and were compared between groups with 
2-sample t tests or Wilcoxon rank-sums tests. Categorical 
variables are given as frequencies and percentages and were 
compared by Fisher exact tests.
Thirty-day survival is based on days past the valve implan-
tation, without consideration of discharge from hospital. The 
proportion of patients censored before 30 days is <1%, and 
pure proportion and Kaplan-Meier estimates of 30-day survival 
differ by ≈0.1%. For ease of presentation and computation, 
30-day survivals were evaluated as pure proportions except 
when otherwise stated.
All statistical analysis was performed with SAS, version 9.2 
(SAS Institute Inc, Cary, NC).
RESULTS
Demographics and Baseline Characteristics
A total of 1950 patients from 80 centers in 10 countries 
were enrolled between July 2014 and October 2015. 
Three patients were excluded from the registry. One 
withdrew consent, and in 2 patients, no SAPIEN 3 was 
used during the procedure. Therefore, a total of 1947 
patients who underwent TAVI with a SAPIEN 3 make up 
the final study cohort of the SOURCE 3 Registry (Fig-
ure 1). Details of their demographic and baseline char-
acteristics are shown in Table 1, and completeness of 
data is presented in Table I in the online-only Data Supple-
ment. The mean age was >81.6±6.6 years, and major 
comorbidities were frequent, resulting in a mean logistic 
EuroSCORE I (logES) of 18.3±13.2%. Of these, 28.9% 
(n=516) according to their logES of <10% would be con-
sidered intermediate-risk patients.
TF access was used in a total of 1695 patients 
(87.1%), whereas 252 patients (12.9%) underwent TAVI 
through a non-TF approach. The access routes chosen 
in this group were transapical (72%), transaortic (21%), 
transcarotid (4%), or transsubclavian (3%; Figure 1).
A comparison of baseline characteristics of these 2 
groups showed that TF patients were older (mean age, 
81.7±6.7 versus 80.8±6.4 years; P=0.048) and more 
often female (49.3% versus 40.1%; P=0.0068). Non-TF 
patients were more often affected by cardiac and non-
cardiac comorbidities, resulting in higher mean logES 
in non-TF patients (21.8% versus 17.8%; P<0.0001). In 
addition, TF patients presented more often with logESs 
<10 (30.5% versus 18.6%; P<0.0001), whereas non-
TF patients were more frequently found to have a logES 
of >30 (24.7% versus 14.5%; P<0.0001; Table 1).
Procedural Data
A total of 1961 SAPIEN 3 valves were implanted, includ-
ing 14 patients (0.7%) who needed a second SAPIEN 3 
at the time of the TAVI procedure. The most common 
valve size used was 26 mm (41.2%), followed by 23 mm 
(36.3%) and 29 mm (22.5%; Table 2).
Most patients (n=1917, 98.5%) underwent TAVI treat-
ment for native aortic valve stenosis, whereas 1.6% of 
patients (n=30) presented with failing aortic valve bio-
prostheses and received valve-in-valve therapy. In 59.9% 
of TF patients (n=1014), the procedure was performed 
under conscious sedation; the remaining cohort was in-
tervened under general anesthesia. Pre-TAVI balloon val-
vuloplasty was used in only 50.6% of patients (TF, 54%; 
non-TF, 28.2%; P<0.0001).
Imaging and assessment of the aortic valve, left ven-
tricle, and aortic root before the TAVI procedure were 
facilitated with transthoracic (n=1578, 81.1%) or trans-
Figure 1. Enrollment and treatment arms of patients 
in the SOURCE 3 Registry (SAPIEN Aortic Bioprosthe-
sis European Outcome).
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esophageal (n=311, 16%) echocardiography and car-
diac computed tomography (n=1607, 82.5%).
Implantation success was high at 98.3% and not dif-
ferent between the 2 access groups (TF, 98.9%; non-TF, 
97.7%). Post-TAVI dilation was performed in 10.4% of TF 
and 12.7% of non-TF patients (P=NS). As a result, aver-
age procedure times, measured as skin-to-skin times, 
were significantly shorter in TF patients compared with 
non-TF patients (69.9±33.8 versus 89.3±47.4 minutes; 
P<0.0001), whereas fluoroscopy time (8.2±7.5 versus 
14.8±7.1 minute) and contrast volume (87.7±52.5 ver-
sus 125.7±59.2 mL) were significantly lower in the non-
TF cohort (P<0.0001). Vascular closure was achieved 
with a percutaneous closure device in most TF patients 
(93.7%).
Procedural Events
Procedural complications were rare and not significantly 
different between the 2 access groups, with unplanned 
valve-in-valve procedures needed in 0.7%, conversion to 
open surgery with sAVR in 0.6%, cardiopulmonary by-
pass in 0.7%, and coronary obstruction and annular rup-
ture reported in 0.4% and 0.2% of patients, respectively 
(Table 3).
Patients who underwent TF TAVI were less often ven-
tilated after they left the procedural theater compared 
with non-TF patients (3.5% versus 19.4%; P<0.0001; 
Table 3).
Antiplatelet/Antithrombotic Management
Although we do not have detailed information on the du-
ration and specific antiplatelet agents used, 34.3% of 
patients were on a single antiplatelet agent, 25.3% were 
on dual antiplatelet therapy, 10.3% were only on antico-
agulation treatment, 14.6% were on a combination of 
antiplatelet and anticoagulation therapy, and 8.9% were 
on none of these medications; in 6.4%, this information 
was not provided.
Table 1. Demographic and Baseline Characteristics, 
TF (n=1695) Versus Non-TF (n=252)
 
TF,
Mean±SD
or n/N (%)
Non-TF,
Mean±SD
or n/N (%)
P 
Value
Age, y 81.7±6.7 80.8±6.4 0.048
Age ≥80 y 1164/1695 (68.7) 157/252 (62.3) 0.051
Female 835/1695 (49.3) 101/252 (40.1) 0.0068
Hypertension 1382/1695 (81.5) 210/252 (83.3) 0.54
Dyslipidemia 907/1995 (53.5) 148/252 (58.7) 0.14
History of smoking 410/1638 (25.0) 96/229 (41.9) <0.0001
Diabetes mellitus 488/1695 (28.8) 87/252 (34.5) 0.065
  Insulin dependent 172/1695 (10.1) 37/252 (14.7) 0.038
Coronary artery 
disease
827/1695 (48.8) 175/252 (69.4) <0.0001
  Myocardial 
infarction
180/1695 (10.6) 48/252 (19.0) <0.0001
  Percutaneous 
coronary 
intervention
553/1694 (32.6) 105/252 (47.7) 0.0054
  Coronary bypass 
grafting
159/1694 (9.4) 62/252 (24.6) <0.0001
Congestive heart 
failure
589/1695 (34.7) 117/252 (46.4) 0.0004
Left ventricular 
ejection fraction 
<30%
91/1434 (6.4) 9/214 (4.2) 0.28
New York Heart 
Association class IV
152/1631 (9.3) 17/244 (7.0) 0.28
Mitral regurgitation 
(moderate to severe)
216/1544 (14.0) 31/228 (13.6) 0.92
Tricuspid 
regurgitation 
(moderate to severe)
152/1438 (10.6) 27/210 (12.9) 0.34
Atrial fibrillation 365/1633 (22.4) 59/240 (24.6) 0.46
Pacemaker 195/1694 (11.5) 34/252 (13.5) 0.35
Chronic obstructive 
pulmonary disease
256/1695 (15.1) 56/252 (22.2) 0.0056
Renal insufficiency 454/1695 (26.8) 80/252 (31.7) 0.11
Severe liver 
disease/cirrhosis
33/1695 (1.9) 2/252 (0.8) 0.31
Porcelain aorta 59/1695 (3.5) 34/252 (13.5) <0.0001
Peripheral vascular 
disease
202/1695 (11.9) 94/252 (37.3) <0.0001
  Peripheral stent 
(femoral, iliac)
25/1694 (1.5) 25/252 (9.9) <0.0001
Stroke 132/1695 (7.8) 31/252 (12.3) 0.02
Transient ischemic 
attack
65/1695 (3.8) 13/252 (5.2) 0.3
Carotid disease 235/1694 (13.9) 65/252 (25.8) <0.0001
  Carotid 
endarterectomy/
stent
53/1694 (3.1) 17/252 (6.7) 0.0096
Coagulopathy 20/1695 (1.2) 3/252 (1.2) >0.99
Mean logES 17.8±12.9 21.8±14.5 <0.0001
  EuroSCORE <10 473/1552 (30.5) 43/231 (18.6) <0.0001
  EuroSCORE >30 225/1552 (14.5) 57/231 (24.7) <0.0001
LogES indicates logistic EuroSCORE; and TF, transfemoral.
(Continued )
Table 1. Continued
 
TF,
Mean±SD
or n/N (%)
Non-TF,
Mean±SD
or n/N (%)
P 
Value
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Thirty-Day Outcomes
Hemodynamics
Hemodynamics improved after TAVI, with a significant de-
crease in mean aortic valve gradients from 43.8±15.5 
to 11.9±5.2 mm Hg (P<0.0001), whereas effective ori-
fice areas increased from 0.71±0.21 to 1.68±45 cm2 
(P<0.0001). Freedom from clinically significant para-
valvular leakage was high, with none/trace observed in 
73.7% and mild seen in 23.3% of patients. Moderate and 
severe paravalvular leakage was reported in 3.0% and 
0.1% of patients, respectively (Figure 2).
Adverse Events
All-cause mortality was lower in the TF than non-TF group 
(1.9% versus 4.0%; P=0.0023). Total cardiovascular mor-
tality was 1.1% and not significantly different between TF 
and non-TF access (Table 3). No 30-day mortality was ob-
served in patients who needed cardiopulmonary bypass 
during the TAVI, but in those who were cardioverted to 
sAVR, mortality increased to 27% (3 of 11).
Causes of death were more often of cardiovascular 
nature in the TF cohort (66% versus 44%) and more of-
ten adjudicated toward intraprocedural complications 
(47% versus 22%). In the non-TF cohort, the majority of 
patient deaths were due to noncardiovascular reasons 
(56% versus 34%).
Strokes were reported in 28 patients (1.4%), of which 
10 (0.5%) were disabling. The incidence was not differ-
ent between the 2 access groups. Although major vas-
cular complications (total, 4.1%) were also not different 
between the cohorts, life-threatening bleeding (9.6% ver-
sus 4.3%; P=0.0004) and new-onset postoperative atri-
al fibrillation (12.5% versus 4.8%; P<0.0001) were more 
common after non-TF TAVI. New permanent pacemakers 
were implanted in 12% of patients, in the majority of pa-
tients triggered by a complete atrioventricular blockage 
(159 of 233, 68.2%). Other commonly observed electro-
cardiographic changes included left-bundle-branch block 
(22.7%, n=53), atrioventricular blockage grade I (31 of 
233, 13.3%) and grade II (17 of 233, 7.3%), and various 
other arrhythmias (33 of 233, 14.2%). Acute degree II 
to III kidney injury according to VARC-2 definitions was 
reported in 22 patients (1.1%) and was more frequent 
after non-TF access (3.2% versus 0.8%; P<0.0001). As 
a result, the median length of stay in the TF group was 
7.0 days (interquartile range, 5–9 days) and thus shorter 
compared with the non-TF group (9 days; interquartile 
range, 7–13 days; P<0.0001; Table 3). Among patients 
considered to be intermediate risk with a logES of <10, 
the incidence of all-cause mortality was 1.7%; cardiovas-
cular mortality, 1.1%; all strokes, 1.7%; major vascular 
complications, 3.8%; and new pacemaker implantation, 
12.6%.
Functional Changes
Comparing preprocedural and postprocedural symp-
toms showed that the proportion of patients with New 
York Heart Association class III/IV symptoms in the TF 
group (73.9% to 10.4%, P<0.0001) and the non-TF 
group (69.8% to 28.0%, P<0.0001) decreased signifi-
cantly (Figure 3).
DISCUSSION
The SOURCE 3 Registry is currently the largest data 
set on the use of the SAPIEN 3 THV, which received CE 
Mark approval in Europe in 2014. The 30-day results 
presented here confirm that its use under so-called 
real-world conditions provides excellent outcomes. All-
cause mortality is lower for TF than non-TF access, but 
for the first time in a SOURCE Registry, cardiovascular 
Table 2. Procedural Data: TF (n=1695) and Non-TF 
(n=252)
 
TF,
Mean±SD
or n/N (%)
Non-TF,
Mean±SD
or n/N (%) P Value
Anesthesia   <0.0001
  General 
anesthesia
667/1694 (39.4) 247/252 (98.0)  
  Conscious 
sedation
1014/1694 (59.9) 4/252 (1.6)  
  Conversion 
from conscious 
sedation to 
general anesthesia
13/1694 (0.8) 1/252 (0.4)  
Absence of 
preballoon 
valvuloplasty
778/1690 (46.0) 181/252 (71.8) <0.0001
Valve size, mm   0.035
  23 633/1694 (37.4) 73/251 (29.1)  
  26 686/1694 (40.5) 116/251 (46.2)  
  29 375/1694 (22.1) 62/251 (24.7)  
  Missing 1/1695 (<1%) 1/252 (<1)  
Correct site 
placement
1670/1688 (98.9) 245/251 (97.6) 0.069
SAPIEN 3-in-
bioprosthesis
27/1669 (1.6) 3/249 (1.2) 0.79
Postdilation 175/1687 (10.4) 32/252 (12.7) 0.27
Vascular closure 
(only for TF)
   
  Surgical 95/1668 (5.7) N/A  
  Closure device 1563/1668 (93.7) N/A  
Procedure time, min 69.9±33.8 89.3±47.4 <0.0001
Fluoroscopy time, 
min
14.8±7.1 8.2±7.5 <0.0001
Contrast volume, mL 125.7±59.2 87.7±52.5 <0.0001
TF indicates transfemoral.
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mortality is not affected by access routes. The over-
all low mortality is likely a result of the low number 
of procedural and 30-day adverse events, including 
disabling stroke, as well as favorable hemodynamics, 
with a very low rate of more than mild paravalvular 
leakage (3.1%).
The increase in implantation success, in previous 
investigations also referred to as procedural success, 
is likely a consequence of the modifications to the SA-
PIEN 3 compared with previous models. The reduction 
in diameter of the introducer devices and their nose 
cones was developed to improve implantation, to fa-
cilitate TF access, and to reduce strokes and vascular 
complications. The sealing was mounted around the 
stent to reduce paravalvular leakage. However, it also 
needs to be recognized that heart teams have gained 
more experience in procedural planning and patient se-
lection. In this respect, 3-dimensional imaging of the 
heart and aortic root such as 3-dimensional echocar-
diography10 and cardiac computed tomography11 has 
been a major step forward and is now implemented as 
routine diagnostics.
The first SOURCE Registry, for which enrollment 
started in 2007 and patients were treated with the SA-
PIEN THV,5 was followed by SOURCE XT,12 which used 
second-generation (SAPIEN XT) prostheses. A compari-
son of the baseline characteristics of patients shows 
that over the last nearly 10 years, the mean age of pa-
tients included in the 3 registries has remained constant 
at ≈81 years (Table 4). Nevertheless, the logES, an indi-
cator of the patient risk profile, has reduced over time. 
Although this is particularly the case for TF patients, the 
logES for the non-TF cohort between SOURCE XT and 
SOURCE 3 remained unchanged and >21. These chang-
es are a result of a reduced number of futile patients, 
with very high logESs, being treated, while at the same 
time the number of intermediate-risk patients in Europe, 
most often suitable for TF access, is rising. Neverthe-
less, final conclusions should not be drawn at this time. 
Future specific subanalyses are on their way to find an-
swers to this and various other unanswered questions.
Implantation success has improved over time and is 
most likely explained by additional clinical experience 
and improvements to the SAPIEN 3 itself. As a result, 
Table 3. Procedural and 30-Day Events and Clinical Outcomes: TF (n=1695) Versus Non-TF 
(n=252)
 
Total,
KM-Estimated 
Event Rates or 
n/N (%)
TF,
KM-Estimated
Event Rates
or n/N (%)
Non-TF,
KM-Estimated 
Event Rates
or n/N (%)
P Value, TF
vs 
Non-TF
Procedural events     
  Valve-in-valve bailout 14/1947 (0.7) 11/1695 (0.7) 3/252 (1.2) 0.41
  Conversion to surgery 11/1947 (0.6) 10/1695 (0.6) 1/252 (0.4) >0.999
  Cardiopulmonary bypass 4/1940 (0.7) 4/1692 (0.2) 0/248 (0) >0.99
  Coronary obstruction 7/1947 (0.4) 6/1695 (0.4) 1/252 (0.4) >0.99
  Annular rupture 3/1947 (0.2) 3/1965 (0.2) 0/252 (0.0) 0.50
30-d Events     
  All-cause mortality 42 (2.2) 32 (1.9) 10 (4.0) 0.0023
  Cardiovascular mortality 20 (1.1) 17 (1.0) 3 (1.2) 0.47
  Major vascular complication 80 (4.1) 72 (4.3) 8 (3.2) 0.37
  Life-threatening bleeding 97 (5.0) 73 (4.3) 24 (9.6) 0.0004
  Myocardial infarction 5 (0.3) 3 (0.2) 2 (0.8) 0.36
  New permanent pacemaker 233 (12.0) 208 (12.3) 25 (10.0) 0.15
  Stroke 28 (1.4) 21 (1.3) 7 (2.8) 0.47
  Disabling stroke 10 (0.5) 8 (0.5) 2 (0.8) 0.58
  Acute kidney injury (II–III) 22 (1.1) 14(0.8) 8 (3.2) <0.0001
  New-onset atrial fibrillation 120 (6.2) 91 (4.8) 29 (12.5) <0.0001
  Ventilated when leaving the procedural theater 109/1945 (5.6) 60/1693 (3.5) 49/252 (19.4) <0.0001
  ICU length of stay (Q1–Q3), d 1 (0–2) 2(1–3) 2 (1–4) 0.0024
  Median length of stay (Q1–Q3), d 7 (5–10) 7 (5–9) 9 (7–13) <0.0001
ICU indicates intensive care unit; KM, Kaplan-Meier; Q, quartile; and TF, transfemoral.
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major vascular complications and the overall stroke rate 
in SOURCE 3 are the lowest reported in a SOURCE Reg-
istry. In this respect, the low profile and nose cone of the 
delivery systems, which also offer an additional oppor-
tunity to perform the procedure without predilation, may 
play a particular role.
Given these baseline characteristics and procedural 
outcomes, it is interesting to see that all-cause 30-day 
mortality between SOURCE and SOURCE XT was quite 
static. Nevertheless, as shown above, SOURCE 3 re-
sults now show lower all-cause mortality for both access 
routes than has been reported with previous-generation 
devices and, for the first time, a cardiovascular 30-day 
mortality that is not different between access routes. 
Given the further reduction in clinically significant paraval-
vular leakage reported in SOURCE 3, it will be interesting 
to see how this translates to 1-year survival and beyond.
Compared with the SOURCE 3 Registry, the 30-day 
outcomes of the approval trial of the SAPIEN 3, includ-
ing 150 patients, were similar in terms of low all-cause 
mortality (2.1%) and cardiac mortality (2.1%) in the TF 
cohort.6 In contrast, non-TF access was still associated 
with higher mortality (all cause, 11.1%; cardiovascular, 
9.3%). However, procedural success was as high (99%), 
and complications such as major vascular events for TF 
(4.2%), disabling strokes (zero), and more than mild para-
valvular leakage (3.5%,) were as low as in SOURCE 3.7
Others have also observed these procedural improve-
ments between SAPIEN XT and SAPIEN 3 in smaller, but 
propensity-matched, cohorts.13,14 Like us, they found 
reduced major vascular complications and paravalvu-
lar leakage with the SAPIEN 3. However, in contrast to 
SOURCE 3, in which the permanent pacemaker rate in-
creased compared with SOURCE XT (12% versus 6%), 
their rate of permanent pacemakers had been stable at 
≈6%14 and 9%.13 This may support the hypothesis that 
the higher pacemaker rate with the SAPIEN 3 is a con-
sequence of the implantation depth, which tends to be 
lower with the SAPIEN 3 prosthesis and not related to 
the device itself. Future trials specifically designed to an-
swer this question should be considered.
At the same time, while data on outcomes with the 
SAPIEN 3 were collected in Europe, an all-comers reg-
istry, including inoperable/high-risk and intermediate-risk 
patients, comparable to SOURCE 3, enrolled patients in 
North America.8 Interestingly, their 30-day results are 
similar to the results presented here. The dominant im-
plantation route was TF (86.9%), and procedural com-
Figure 2. A, Hemodynamic outcomes at 30 days; B, 
paravalvular leakage at 30 days. 
EOA indicates effective orifice area.
Figure 3. Functional improve-
ments at 30 days.
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plications were low. All-cause mortality was reported 
at 2.2% (high-risk patients) and 1.1% (intermediate-risk 
patients), whereas cardiovascular mortality was lowest 
in the intermediate-risk group (0.9% versus 1.4%). As in 
SOURCE 3, the difference in mortality between TF and 
non-TF was less than previously reported and nonexistent 
in the intermediate cohort. Hemodynamic results at 30 
days were very similar to SOURCE 3, with a very low rate 
of paravalvular leakage (moderate degree, 3.4%; severe 
degree, none). The similarity in outcomes makes it likely 
that the SAPIEN 3 device has been improved to a level 
where the implantation has become less investigator de-
pendent, an ultimate goal of any device used in medicine.
Implications
The excellent outcomes with the SAPIEN 3 reported here 
and the recently published propensity-matched compari-
son of intermediate-risk patients treated with the SAPIEN 
3 with patients who underwent sAVR in PARTNER 29 may 
stimulate heart teams to consider TAVI in even lower-risk 
patients. Although this may be justified in elderly patients 
(mean age in most TAVI trials like the SOURCE Regis-
tries is ≈80 years), one should be careful in extrapolat-
ing these results to younger patients and other devices 
because their risk profile may be different.
For example, complications such as pacemaker im-
plantations after TAVI have different consequences for 
younger patients. The risk of stroke may not decrease 
as much with lower age in TAVI as it decreases with age 
in surgery because the mechanisms of cerebral isch-
emia during the procedure are very different. In addition, 
durability is crucial when considering treating younger 
patients. Data beyond 10 years after THV implantation 
are currently not available, and in SOURCE 3, follow-up 
is planned for a total of 5 years. In the first instance, it 
would be safer to focus on elderly low-risk patients who 
benefit most from the advantages of TAVI, while they 
are not so much at risk from possible unknown conse-
quences.
Limitations
The SOURCE 3 Registry is a clinical registry, and all out-
comes are self-reported by the participating centers. 
The implanting teams made the decision about the ac-
cess route, although it is acknowledged that the majority 
of participating centers perform TAVI via TF access if 
feasible. The participating centers committed to submit 
consecutive series of patients treated with the SAPIEN 3, 
but this was not controlled in detail.
Strokes are self-reported, and no routine neurological 
assessment was performed in all patients. However, all 
clinical events, including strokes, were adjudicated by an 
independent committee.
Conclusions
The 30-day results of the SOURCE 3 Registry demon-
strate that TAVI with the SAPIEN 3 results in high pro-
cedural success with low procedural complications and 
excellent postimplantation hemodynamics. This, in com-
bination with the growing experience of patient selection, 
procedure planning, execution, and postoperative care, 
has led to one of the best short-term outcomes ever re-
ported after TAVI. These outcomes not only demonstrate 
the short-term advantages of this third-generation THV in 
clinical practice but also should be used as a benchmark 
for other THV devices entering the market.
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Table 4. Comparison of 30-Day Key Parameters 
From the 3 SOURCE Registries
 SOURCE
SOURCE 
XT SOURCE 3
Age, y 81.1 81.4±6.6 81.6±6.6
LogES 27.6 20.4±12.4 18.3±13.2
  TF 25.7±14.5 19.8±11.6 17.8±12.9
  Non-TF 29.1±16.3 21.9±13.4 21.8±14.5
TF access, % 44.6 62.7 87.1
Implantation/procedural 
success, %
93.8 95.5 98.3
New permanent pacemaker, % 7 6 12
Major vascular complications, % 10.6 6.5 4.1
Stroke, % 2.4 3.6 1.4
All-cause mortality, % 8.5 6.3 2.2
  TF 6.3 4.2 1.9
  Non-TF 10.3 10 4.0
Cardiovascular mortality, % N/A 3.0 1.1
  TF N/A 1.7 1.0
  Non-TF N/A 5.7 1.2
Paravalvular leakage 
(moderate–severe)
N/A 5.5 3.1
LogES indicates logistic EuroSCORE; SOURCE, SAPIEN Aortic 
Bioprosthesis European Outcome; and TF, transfemoral.
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SUPPLEMENTAL MATERIAL 
 
 
SUPPLEMENTAL FILE 1 
 
SOURCE 3 Registry Administration 
Principal Investigators 
Olaf Wendler, King’s Health Partners, London/UK 
Alec Vahanian (from 2015), Hôpital Bichat, Paris/France 
Martyn Thomas (until 2015), formerly St Thomas’ Hospital, London/UK 
Steering Committee 
Helmut Baumgartner, University Clinics, Muenster/Germany 
Nicolas Dumonteil, Clinique Pasteur, Toulouse/France 
Leo Ihlberg, University Central Hospital, Helsinki/Finland 
Franz-Josef Neumann, University Heart Center, Bad Krozingen/Germany 
Gerhard Schymik, Municipal Hospital, Karlsruhe/Germany 
Giuseppe Tarantini, Policlinico Universitario, Padova/Italy 
Hendrik Treede, University Clinics, Halle/Germany 
Clinical Events Committee 
Chairman:  Philip Urban, Hôpital de La Tour, Meyrin/Switzerland 
  
SUPPLEMENTAL FILE 2 
Participating Centers 
Site Name Principal Investigator Enrolment 
   
Municipal Hospital, Karlsruhe, Germany Gerhard Schymik 133 
King's Health Partners, London, UK Olaf Wendler / Simon Redwood 
 
107 
Kerckhoff Clinic, Bad Nauheim, Germany Thomas Walther 99 
German Heart Center, Munich, Germany Christian Hengstenberg / Sabine Bleiziffer 
 
92 
Heart Center, Bad Segeberg, Germany Mohamed Abdel-Wahab 66 
University Clinics (UKE), Hamburg, Germany Hendrik Treede 61 
Institut Jacques Cartier, Massy, France Thierry Lefevre 60 
University Hospital, Angers, France Frederic Pinaud 52 
University Hospital, Kiel, Germany Derk Frank 52 
Aarhus University Hospital, Skejby, Denmark Christian Terkelsen 49 
Asklepios Clinic, Hamburg, Germany Christian Frerker 48 
Charles Nicolle Hospital, Rouen, France Helene Eltchaninoff 48 
Heart Center, Leipzig, Germany Axel Linke / David Holzhey 41 
University Hospital La Timone, Marseille, 
France Frederic Collart 40 
Institut Mutualiste Montsouris, Paris, France Christophe Caussin 40 
University Hospital, Strasbourg, France Patrick Ohlmann 38 
University Hospital La Cavalle Blanche, 
Brest, France Martine Gilard 37 
Centre Cardiologique du Nord, Saint-Denis, 
France Franck Digne 36 
University Clinics, Ulm, Germany Jochen Woehrle 35 
University Hospital, Clermont-Ferrand, 
France Geraud Souteyrand 34 
University Hospital Laennec, Nantes, France Vincent Letocart 34 
Heart Center Brandenburg, Bernau, Germany Christian Butter/Prof. Johannes Albes 
 
33 
University Hospital, Bern, Switzerland Stephan Windecker 33 
University Clinics, Muenster, Germany Helmut Baumgartner 33 
Helios Clinics, Siegburg, Germany Peter Boekstegers 32 
University Hospital, Lille, France Eric VanBelle 30 
University Medical Center, Utrecht, The 
Netherlands Pieter Stella 30 
DHZ, Bad Oeynhausen, Germany Jochen Boergermann /  Werner Scholtz 
 
29 
Hopital Bichat Paris Alec Vahanian 29 
Hospital Clinics, Augsburg, Germany Christian Thilo 28 
University Hospital Rangueil, Toulouse, 
France Didier Carrie 27 
University Hospital Jean Minjoz, Besancon, 
France Francois Schiele 24 
Queen Elisabeth Hospital, Birmingham, 
United Kingdom Sagar Doshi 24 
University Hospital Bocage, Dijon, France Yves Cottin 23 
Saint-Gatien Clinic, Tours, France Stephan Chassaing 23 
University Hospital, Grenoble, France Bernard Bertrand 22 
Hospices Civils de Lyon, France Jean Obadia / Raphael 
Dauphin 
21 
 Robert-Bosch Hospital, Stuttgart, Germany Hardy Baumbach  21 
Clairval Clinic, Marseille, France Frederic Collet 20 
Klinikum Karlsburg, Germany Georg Wollert 19 
Niederrhein Heart Center, Duisburg, 
Germany Wolfgang Schoels 18 
Universitaetsklinikum, Regensburg, Germany Kurt Debl 16 
Hopital Saint Joseph, Marseille, France Patrick Joly 15 
Oulu University Hospital, Oulu, Finland Matti Niemela 15 
Johannes Gutenberg Universitaet, Mainz, 
Germany Ulrich Hink 14 
Universitaetsspital, Basel, Switzerland Raban Jeger 14 
Centro Cardiologico Monzino, Milano, Italy Antonio Bartorelli / Francesco Alamanni 
 
12 
Klinik im Park, Zuerich, Switzerland Franz Amann 12 
Surgical Center Marie Lannelongue, Le 
Plessis-Robinson, France Said Ghostine 11 
Clinique Ambroise Pare, Neuilly, France Philippe Allouch / Christophe Bensouda  
 
11 
Helsinki University Hospital, Helsinki, Finland Leo Ihlberg 9 
Herz-Zentrum, Bad Krozingen, Germany Heinz Buettner 8 
Royal Infirmary of Edinburgh, Edinburgh, 
United Kingdom Renzo Pessotto 8 
CH Pitie Salpetriere, Paris, France Pascal Le Prince 7 
HerzKlinik Hirslanden HKH, Zuerich, 
Switzerland Roberto Corti   7 
Hopital Prive Parly II, Le Chesnay, France Arnaud Jegou 7 
University Hospital, Koeln Germany Tanja Rudolph / Navid Madershahian 
 
7 
Zentralklinik, Bad Berka, Germany Thomas Kuntze 7 
Azienda A.R.N.A.S. Ospedale Civico di 
Palermo, Palermo, Italy Amerigo Stabile  6 
Papworth Hospital, United Kingdom Cameron Densem 6 
Polyclinique Bois, Lille, France Maxence Delomez  6 
Universitaetsklinik, Erlangen, Germany Martin Arnold 6 
Ospedale San Raffaele, Milano, Italy Antonio Colombo 5 
Herz und Gefaess Klinik, Bad Neustadt, 
Germany Diegeler, Anno 4 
University Hospital, Nancy, France Thierry Folliguet 3 
Derriford Hospital, Plymouth, United Kingdom Clinton Lloyd 3 
Klinikum der Stadt, Ludwigshafen am Rhein, 
Germany Ralf Zahn 3 
Schuechtermann Klinik, Bad Rothenfelde, 
Germany Norbert Franz 3 
Clinique Saint-Augustin, Bordeaux, France Olivier Darremont 2 
National Institute Cardiovascular Disease, 
Slovakia Michal Hulman 1 
Policlinica Gipuzkoa Hospital, Spain Mariano Larman 1 
 
  
Supplemental Table 1: Demographic, Baseline Characteristics and 
Missing Data of the Total Cohort (N=1947) 
 Mean ± SD or n/N (%) % Missing 
 
Age (years) 
 
81.6 ±6.6 0/1947 (0%) 
Age ≥80 years 1321/1947 (67.8%) 
 
0/1947 (0%) 
Female 936/1947 (48.1%) 
 
0/1947 (0%) 
Hypertension 1592/1947 (81.8%) 
 
0/1947 (0%) 
Dyslipidemia 
 
1055/1947 (54.2%) 0/1947 (0%) 
History of smoking 506/1867 (27.2%) 
 
80/1947 (4.1%) 
Diabetes 575/1947 (29.5%) 
 
0/1947 (0%) 
   Insulin-dependent 209/1947 (10.7%) 
 
0/1947 (0%) 
Coronary artery disease 1002/1947 (51.5%) 
 
0/1947 (0%) 
   Myocardial Infarction 228/1947 (11.7%) 
 
0/1947 (0%) 
   Percutaneous coronary 
   Intervention 
 
658/1946 (33.8%) 
 
1/1947 (<1%) 
   Coronary bypass grafting 221/1946 (11.4%) 
 
1/1947 (<1%) 
Congestive heart failure 706/1947 (36.3%) 
 
0/1947 (0%) 
Left Ventricular Ejection Fraction  
< 30% 
 
100/1648 (6.1%) 299/1947 (15.4%) 
New York Heart Association  
Class IV 
 
169/1879 (9.0%) 
 
73/1947 (3.8%) 
Mitral regurgitation (moderate to 247/1772 (13.9%) 175/1947 (9.0%) 
severe) 
 
Tricuspid  regurgitation (moderate to 
severe) 
 
179/1648 (10.9%) 299/1947 (15.4%) 
Atrial fibrillation 
 
424/1873 (22.6%) 74/1947 (3.8%) 
Pacemaker 
 
229/1946 (11.8%) 1/1947 (<1%) 
Chronic obstructive 
pulmonary disease 
 
312/1947 (16.0%) 0/1947 (0%) 
Renal insufficiency 
 
534/1947 (27.4%) 0/1947 (0%) 
Severe liver disease/cirrhosis 
 
35/1947 (1.8%) 0/1947 (0%) 
Porcelain aorta 
 
93/1947 (4.8%) 0/1947 (0%) 
Peripheral vascular disease 
 
296/1947 (15.2%) 0/1947 (0%) 
   Peripheral stent (femoral, iliac) 
 
50/1946 (2.6%) 1/1947 (<1%) 
Stroke 
 
163/1947 (8.4%) 0/1947 (0%) 
Transient ischemic attack 
 
78/1947 (4.0%) 0/1947 (0%) 
Carotid disease 
 
300/1946 (15.4%) 1/1947 (<1%) 
   Carotid endartectomy/stent 
 
70/1946 (3.6%) 1/1947 (<1%) 
Coagulopathy 
 
23/1947 (1.2%) 0/1947 (0%) 
Mean Logistic EuroSCORE 
 
18.3 ±13.2 163/1947 (8.4%) 
   EuroSCORE <10 
 
516/1783 (28.9%) 
 163/1947 (8.4%) 
   EuroSCORE >30 
 
282/1783 (15.8%)  163/1947 (8.4%) 
 
